Last updated: May 25, 2026
Sulfacetamide sodium is a long-established small-molecule antibiotic used in topical ophthalmic, topical dermatologic, and (historically) some systemic settings. The practical supplier landscape is best mapped by (1) active pharmaceutical ingredient (API) producers and (2) finished-dose manufacturers that source API and hold FDA-listed products (where applicable).
Below is a supplier map by supply-chain role. If you need an exact “who supplies the API for brand X strength/formulation” list, the only defensible approach is an API maker match from documentable sources (e.g., Drug Master Files, supplier disclosures, or direct regulatory filings linked to specific finished products). Without that linkage, listing API makers by name risks false attribution.
Which companies supply sulfacetamide sodium API?
Answer: Reliable API supplier identification requires API DMF linking or direct regulatory citations tied to specific finished products. Without product-DMF linkage, API “supplier” lists are not purchase-verifiable.
API supply chain structure
- DMF holders / API manufacturers
Sulfacetamide sodium API is typically supplied under Drug Master File cover to finished-dose manufacturers. Finished-dose firms often select suppliers through qualification and ongoing quality agreements aligned to cGMP and compendial specs.
- Contract manufacturers (CMOs) and repackers
Some companies produce API directly; others run conversion, crystallization, milling, packaging, and analytical release under commercial contracts.
- Formulation finishers
For ophthalmic and topical products, the bottleneck is usually not API availability but the ability to meet sterility/sterile fill (ophthalmics), preservative efficacy, and stability for the finished dosage form.
What “supplier” should mean for procurement
For procurement and sourcing, the supplier list should be split into:
- API manufacturer (DMF holder): who produces sulfacetamide sodium API.
- Finished-dose manufacturer: who manufactures the drug product and holds the FDA application.
- Wholesalers and distributors: who controls market access and lead times.
Who makes FDA-listed sulfacetamide sodium ophthalmic products?
Answer: Finished-dose manufacturers are identifiable from FDA labeling and listing records, but naming them requires direct Orange Book or FDA NDC/listing pulls tied to the exact strength and dosage form (solution, ointment, suspension).
Key product categories
- Ophthalmic solutions/ointments (sterile or semi-solid formats)
- Dermatologic topical solutions/lotions (often with keratolytics or anti-inflammatory co-formulation)
- Historical systemic use (limited current routine procurement relevance)
Procurement implication
Even when multiple firms can source API, the same NDC can be supplied by only a subset of manufacturers due to sterile manufacturing capacity and regulatory responsibility.
What suppliers cover sulfacetamide sodium topical dermatologic products?
Answer: The dermatologic market typically has more manufacturers for finished-dose forms than the ophthalmic market. Still, a defensible supplier list depends on the exact product presentation and NDC.
Formulation-dependent sourcing
Sulfacetamide sodium topical products differ in:
- solvent system and preservatives
- concentration (e.g., 10% class products)
- packaging (tube/dispensing bottle)
- stability and microbial control approach
These factors determine which finishers can qualify and which API sources meet release specs.
How many API suppliers exist for sulfacetamide sodium and how concentrated is supply?
Answer: The market is generally less concentrated than newer patented antibiotics, but concentration varies by finished-dose sterilization needs (ophthalmics) and by concentration and formulation type.
Practical concentration drivers
- whether sterile manufacturing is required
- whether the dosage form is pharmacy-compounded or commercial
- whether the supplier network supports compendial assays and impurity profiles
- whether the supplier has DMF-to-finished-dose linkage already on file
What are the most common supplier risks for sulfacetamide sodium?
Answer: Supply risks are mainly quality-control and manufacturing continuity risks, not patent barriers.
Risk categories
- Sterile manufacturing outages for ophthalmic products
- API impurity drift across batches (process changes, sourcing changes)
- Regulatory/quality holds if deviations are found during inspections
- Packaging and scale-up constraints during demand spikes
Which distributors stock sulfacetamide sodium in the US and EU?
Answer: Distributor coverage is typically broad for long-listed generics, but the specific availability depends on NDC-level replenishment and product-by-product manufacturing cycles. A credible distributor list must be grounded in specific NDC inventory records or tender documentation.
Market mechanics
- Wholesalers often carry multiple NDCs that are therapeutically interchangeable
- Shortages usually occur at the finished-dose level rather than API level
How to qualify a sulfacetamide sodium supplier quickly for procurement?
Answer: Qualification should be evidence-based and traceable to regulatory and quality documentation.
Evidence pack procurement teams typically require
- CoA with assay and impurity profile (API and/or finished product)
- GMP certificate for the manufacturing site
- DMF or application linkage indicating regulatory acceptance pathway (for API use)
- Stability and compatibility documentation for the target formulation class
- Change control commitments and notification SLAs
Key Takeaways
- “Supplier” for sulfacetamide sodium must be defined as API manufacturer vs finished-dose manufacturer vs distributor, because the names and roles differ materially.
- A precise, defensible list of API suppliers requires DMF or finished-dose regulatory linkage; otherwise supplier attribution is not purchase-verifiable.
- For procurement, the main bottlenecks are usually finished-dose manufacturing constraints, especially for sterile ophthalmic products, and batch-to-batch impurity control for the API.
FAQs
1) What should I request to verify sulfacetamide sodium API sourcing?
Request a supplier-specific CoA, site GMP evidence, and DMF linkage or documented regulatory acceptance for your intended finished-dose pathway.
2) Are sulfacetamide sodium ophthalmic shortages usually API-driven?
Usually not. Shortages more often arise from finished-dose sterile manufacturing capacity, labeling/NDC-level replenishment, or quality holds.
3) How do I compare sulfacetamide sodium suppliers across quality performance?
Compare impurity profiles, out-of-spec rates, change control history, stability data, and inspection outcomes tied to the manufacturing site.
4) Can one API supplier support multiple sulfacetamide sodium formulations?
Often yes, but feasibility depends on grade/specs, impurity profile, and downstream stability/compatibility requirements for each dosage form.
5) What formulation details most affect supplier qualification for sulfacetamide sodium?
Concentration, solvent/preservative system, sterility requirements (ophthalmic), and packaging material compatibility drive qualification.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drugs@FDA. U.S. Food and Drug Administration.
- FDA. Drug Master Files (DMF). U.S. Food and Drug Administration.
